Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF Combined With AMD3100 in Healthy Volunteers
NCT00082329Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 2004
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor in hematopoietic stem cell mobilization, sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Ratio of Th1 versus Th2 T-cells in apheresis products at Day 5 and Number of Participants With Successful Apheresis Collection Following Combination of AMD3100 and G-CSF at Day 1. Started Jun 2004; status: completed.
02
Drugs
plerixafor
03
Conditions
hematopoietic stem cell mobilization
Beyond the preview
Go deeper on NCT00082329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082329.